GOLPH3 predicts survival of colorectal cancer patients treated with 5-fluorouracil-based adjuvant chemotherapy by Zaozao Wang et al.
Wang et al. Journal of Translational Medicine 2014, 12:15
http://www.translational-medicine.com/content/12/1/15RESEARCH Open AccessGOLPH3 predicts survival of colorectal cancer
patients treated with 5-fluorouracil-based adjuvant
chemotherapy
Zaozao Wang1†, Beihai Jiang1†, Lei Chen1†, Jiabo Di1, Ming Cui1, Maoxing Liu1, Yiyuan Ma1, Hong Yang1,
Jiadi Xing1, Chenghai Zhang1, Zhendan Yao1, Nan Zhang1, Bin Dong2, Jiafu Ji3 and Xiangqian Su1*Abstract
Background: Golgi phosphoprotein 3 (GOLPH3) has been validated as a potent oncogene involved in the progression
of many types of solid tumors, and its overexpression is associated with poor clinical outcome in many cancers.
However, it is still unknown the association of GOLPH3 expression with the prognosis of colorectal cancer (CRC)
patients who received 5-fluorouracil (5-FU)-based adjuvant chemotherapy.
Methods: The expression of GOLPH3 was determined by qRT-PCR and immunohistochemistry in colorectal tissues
from CRC patients treated with 5-FU based adjuvant chemotherapy after surgery. The association of GOLPH3 with
clinicopathologic features and prognosis was analysed. The effects of GOLPH3 on 5-FU sensitivity were examined
in CRC cell lines.
Results: GOLPH3 expression was elevated in CRC tissues compared with matched adjacent noncancerous tissues.
Kaplan-Meier survival curves indicated that high GOLPH3 expression was significantly associated with prolonged
disease-free survival (DFS, P = 0.002) and overall survival (OS, P = 0.011) in patients who received 5-FU-based
adjuvant chemotherapy. Moreover, multivariate analysis showed that GOLPH3 expression was an independent
prognostic factor for DFS in CRC patients treated with 5-FU-based chemotherapy (HR, 0.468; 95%CI, 0.222-0.987;
P = 0.046). In vitro, overexpression of GOLPH3 facilitated the 5-FU chemosensitivity in CRC cells; while siRNA-mediated
knockdown of GOLPH3 reduced the sensitivity of CRC cells to 5-FU-induced apoptosis.
Conclusions: Our results suggest that GOLPH3 is associated with prognosis in CRC patients treated with postoperative
5-FU-based adjuvant chemotherapy, and may serve as a potential indicator to predict 5-FU chemosensitivity.
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Colorectal cancer (CRC) is the third most common cancer
worldwide and the second leading cause of cancer deaths
in Europe and North America [1,2]. The 5-year survival
rate of CRC has been improved over the past two decades
because of progress in early diagnosis and treatment
modalities [1-3]. Currently, the usage of fluorouracil-
based adjuvant chemotherapy after resection of CRC is* Correspondence: suxiangqian@bjmu.edu.cn
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reproduction in any medium, provided the orconsidered as a major therapeutic approach in prolonging
patient survival; and the standard first-line treatment for
CRC is the combination therapy of 5-fluorouracil (5-FU)
with DNA-damaging agent oxaliplatin [2-4]. However,
a proportion of patients fail to benefit from adjuvant
chemotherapy, either as a result of drug resistance or due
to chemotherapy-induced toxicity [4-6]. Consequently,
there is an urgent need to identify prognostic factors and
markers that can predict chemotherapy sensitivity or re-
sistance in order to select patients that most likely to be
benefit from the adjuvant chemotherapy before treatment.
Golgi phosphoprotein 3 (GOLPH3) was initially identi-
fied as a Golgi membrane protein. It is highly conserved
in a range of organisms from yeast to humans and playstd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Association between GOLPH3 expression and
clinicopathological variables of CRC patients treated with
5-FU-based adjuvant chemotherapy
Variables Cases GOLPH3 expression P
Low High
Age
<60 yr 58 32 26 0.718
≥60 yr 72 42 30
Gender
Female 50 21 29 0.007
Male 80 53 27
Tumor location
Colon 104 62 42 0.215
Rectum 26 12 14
Tumor size
≤4 cm 43 24 19 0.858
>4 cm 87 50 37
Depth of Invasion
T1/T2 13 7 6 0.813
T3/T4 117 67 50
Lymph node metastasis
Negative 50 24 26 0.104
Positive 80 50 30
Distant metastasis
Negative 105 56 49 0.090
Positive 25 18 7
TNM stage
II 45 21 24 0.086
III/IV 85 53 32
Histological type
Adenocarcinoma 121 70 51 0.498
Mucinous 9 4 5
Tumor differentiation
Well 17 10 7 0.812
Moderate 87 49 38
Poor 17 11 6
Unknown 9
Recurrence
Negative 83 42 41 0.006
Positive 42 32 10
Unknown 5
Survival
Alive 82 40 42 0.014
Dead 48 34 14
P values in bold were statistically significant.
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Recently it has been validated as a potent oncogene fre-
quently targeted for copy number gain at chromosome
5p13 in several human cancers, including colorectal
cancer [10]. Also, it has been reported that GOLPH3
overexpression promotes cell proliferation and tumori-
genesis by activating mTOR signaling, enhancing AKT
activity, as well as decreasing FOXO1 transcriptional
activity [10,11]. Importantly, the ability of GOLPH3 to
modulate rapamycin-induced tumor cell death identi-
fies it as a potential positive predictor of rapamycin
sensitivity in tumor therapy [10]. Moreover, high ex-
pression of GOLPH3 has been shown to be associated
with poor prognosis in breast cancer, esophageal squa-
mous cell carcinoma (ESCC), oral tongue cancer, gas-
tric cancer, prostate cancer, glioblastoma multiforme,
gliomas, and rhabdomyosarcoma[11-18] . However, the
clinical relevance of GOLPH3 in patients with CRC
remains largely unknown.
In the current study, we examined the expression of
GOLPH3 in CRC in order to determine its correlation
with clinical characteristics and prognosis. Moreover, we
investigate the potential association between 5-FU che-
mosensitivity of CRC cells and GOLPH3 level. Our
results suggest that increased expression of GOLPH3
correlates with favourable prognosis in patients treated
with 5-FU-based adjuvant chemotherapy and predicts
higher 5-FU sensitivity in CRC cells. Taken together, our
results suggest that GOLPH3 may serve as a potential
indicator to predict 5-FU chemosensitivity.
Methods
Patients and tissue specimens
This retrospective study included 130 CRC patients with
available tumour specimens who received surgical resec-
tion followed by 5-FU-based post-operative adjuvant
chemotherapy from January 2004 to December 2006, in
Peking University Cancer Hospital & Institute. Patients
treated with pre-operative radiotherapy or adjuvant
chemotherapy were excluded from this study. A total of
130 CRC tissues and 75 matched non-cancerous tissues
were obtained from resected tumors and adjacent tis-
sues, respectively. Then, all the tissues were fixed in
buffered formalin and embedded in paraffin. The CRC
and normal tissues were all pathologically confirmed.
TNM stages of patients were determined according to
the American Joint Committee on Cancer (AJCC) classi-
fication guidelines. The clinicopathological characteris-
tics of the patient cohort are summarized in Table 1. For
all patients, combination chemotherapy of oxaliplatin,
5-FU, with leucovorin was started within 4 to 8 weeks
after surgery, according to their recovery. The treatment
cycle was repeated every 2 weeks for 12 cycles. All patients
were followed until August 2012. The median follow-up
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the matched adjacent noncancerous tissues were fresh-
frozen tissues stored at −80°C for quantitative reverse
transcription-PCR (qRT-PCR) analysis. The collection of
tissue samples was approved and supervised by the Re-
search Ethics Committee of Peking University Cancer
Hospital & Institute. Written informed consents were
obtained from all patients prior to surgery.
Quantitative reverse transcription-PCR (qRT-PCR)
Total RNA from colorectal tissues or CRC cells were ex-
tracted using Trizol (Invitrogen, Carlsbad, CA, USA). The
isolated total RNA was transcribed into cDNA using a
reverse transcription kit (Promega, Madison, WI, USA) ac-
cording to the manufacturer’s instructions. The synthesized
cDNA was used as templates in qRT-PCR to evaluate the
relative mRNA levels of GOLPH3 and GAPDH (as internal
control) using primers summarized in Additional file 1:
Table S1. The primers were conjungated with SYBR Green
PCR Master Mix (Toyobo Co. Ltd., Osaka, Japan) and the
PCR was performed with the ABI 7500 real-time PCR sys-
tem (Life Technologies, Carlsbad, California, USA). Data
were analysed using ABI 7500 V 2.0.6 software and pre-
sented in terms of relative quantification (RQ) to GAPDH,
based on calculations of 2-ΔCt where ΔCt = Ct (Target) -Ct
(Reference). Fold change was calculated by the 2 -ΔΔCt
method [19]. Each sample was examined in triplicate.
Immunohistochemistry
Paraffin-embedded CRC specimens were sliced into
4 μm sections. Immunohistochemical staining was per-
formed as described [20] with the primary rabbit poly-
clonal antibody against GOLPH3 (Cat#: 19112-1-AP;
1:400, Proteintech). The visualization signal was de-
veloped with diaminobenzidine (Sigma). Sections were
counterstained with hematoxylin. Tissue staining with
purified IgG from normal rabbit serum was used as a
negative control. GOLPH3 staining was evaluated by two
experienced pathologists, BD and ZL, independently with-
out any knowledge of the clinical data. The total GOLPH3
immunostaining score was calculated both as the percent-
age of positive cells, and the intensity of cytoplasmic stain-
ing: The proportion of positive tumor cell was scored as:
0, no positive tumor cells; 1, 1%–10% positive tumor cells;
2, 11%–35% positive tumor cells; 3, 36%–70% positive
tumor cells; and 4, >70% positive tumor cells. Staining in-
tensity was scored as: 0, no staining; 1, weak staining (light
yellow); 2, moderate staining (yellow brown); and 3, strong
staining (brown). The staining index for GOLPH3 expres-
sion in colorectal cancer lesions was calculated by multi-
plying the two scores obtained for each sample and
obtained values of 0, 1, 2, 3, 4, 6, 9, or 12 [13]. A minimal
measurement of score six was predetermined as high
GOLPH3 expression.Cell lines and cell culture
Human CRC cell lines SW480, RKO, LoVo, HT29, and
HCT116 were purchased from American Type Culture
Collection (ATCC, Manassas, VA). Human CRC cell
lines SW480, RKO and HT29 were grown in RPMI-
1640 (Gibco), while LoVo and HCT116 were cultured
in DMEM medium (Gibco). All the media were supple-
mented with 10% fetal bovine serum (FBS, PAA) and
antibiotics (100 units/mL penicillin and 100 μg/mL
streptomycin) at 37°C in a humidified incubator with
5% CO2.
Plasmid and siRNA transfections
The GOLPH3 expressing plasmid (pCMV-Myc-GOLPH3)
was constructed by subcloning a PCR product encoding
full-length human GOLPH3 cDNA into the pCMV-Myc
plasmid. The GOLPH3-targeting siRNA and the negative
control siRNA were designed and purchased from Shanghai
Gene Pharma (Shanghai, China). The primer sequences
used for subcloning, sequences of GOLPH3 siRNA and the
control were summarized in Additional file 1: Table S1.
RKO and LoVo cells were transiently transfected with the
pCMV-Myc-GOLPH3 plasmid or siRNAs using Lipofecta-
mine™ 2000 (Invitrogen) according to the manufacturer’s
protocol. Transfected cells were incubated for 24 h before
further treatment.
Methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay
MTT assay was used to determine cell sensitivity to 5-
FU. RKO and LoVo cells transfected with GOLPH3 ex-
pressing plasmid or GOLPH3 siRNA were seeded 4000
cells/well in 96-well plates and incubated at 37°C for
24 h. Then the medium was replaced with 150 μL of
fresh medium containing 5-FU of 0, 12.5, 25, 50, 100
and 200 μM. After 48 h exposure, MTT dye was added
to each well with the final concentration of 5 mg/mL,
and then the cells were incubated for another 4 h at 37°
C. Before measurement, the resultant formazan crystals
were dissolved by replacing the culture medium with
equal volume of dimethylsulfoxide (DMSO). The spec-
trometric absorbance at 570 nm was measured with a
microplate reader (Bio-Rad, USA). The inhibition ratio
was calculated as [(OD value of control - OD value of
the sample)/OD value of control] × 100%. The experi-
ment was repeated three times.
Apoptosis analysis
Apoptosis was determined using the PI/Annexin V
dual staining kit (Biosea Biotechnology, Beijing, China)
according to the manufacturer’s instructions. Briefly,
5 × 105 cells were plated in each well of six-well plates
and incubated at 37°C for 24 h. After being transfected
with GOLPH3 expressing plasmid or GOLPH3 siRNA,
the CRC cells were then exposed to 0 or 200 μM of
Wang et al. Journal of Translational Medicine 2014, 12:15 Page 4 of 11
http://www.translational-medicine.com/content/12/1/155-FU, and incubated for 48 h. The cells were then har-
vested and stained with AnnexinV/fluorescein isothio-
cyanate (FITC) and propidium iodide (PI) and subjected
to flow cytometry analysis using FACSAria (BD, Franklin
Lakes, NJ).
Western blot
After transfection, RKO and LoVo cells were exposed
to 0, 100 and 200 μM of 5-FU or 0, 2 and 20 μM of
paclitaxel. After 48 h incubation, cells were harvest
and total protein (100 μg) isolated from cells were elec-
trophoresed followed by electrotransferring onto a
nitrocellulose membrane. The expression of proteins
was detected using primary antibody against GOLPH3
(Cat#: 19112-1-AP; 1:500; Proteintech), PARP (Cat#:
9542; 1:1000; Cell Signaling Technology), and β-actin
(Cat#: TA-09; 1:1000; ZSGB-BIO). The signal was de-
tected by the ECL Western blot detection kit (Amersham,
Little Chalfont, UK). Band intensity was quantified using
NIH Scion Image software and normalized to β-actin.
Statistical analysis
Statistical analysis was performed using SPSS software
(version 13.0, SPSS, Inc., Chicago, IL). Differences in
mRNA expression between tumor samples and the
matched adjacent noncancerous tissue samples were
evaluated using paired-sample t-tests. Pearson’s chi
square and Fisher’s exact tests were used to analyse the
correlation between GOLPH3 expression and clinico-
pathological characteristics. Survival was determined
using the Kaplan-Meier methods and compared with
the log-rank test. Univariate and multivariate survival
analyses were performed using the Cox proportional
hazard regression model. Two-sided values of P < 0.05
were considered statistically significant.Figure 1 Expression of GOLPH3 in colorectal tissues. (A) GOLPH3 mRN
tissues (Normal) was detected by qRT-PCR. The relative expression of GOL
immunohistochemical images indicate strong (a) or moderate (c) GOLPH3
matched noncancerous tissues adjacent to tumors (N). Magnification is 20Results
GOLPH3 expression and association with
clinicopathological characteristics in CRC
In this study, we examined GOLPH3 mRNA levels in
matched cancerous and adjacent noncancerous colo-
rectal tissues from 30 CRC patients. qRT-PCR results
showed that GOLPH3 transcripts were significantly ele-
vated in cancerous tissues than in matched adjacent
noncancerous tissues (P = 0.003, Figure 1A). Moreover,
we measured GOLPH3 protein expression by immu-
nohistochemistry in 130 cases. Consistent with mRNA
expression, high GOLPH3 expression was detected in
56 out of 130 (43.1%) CRC tissues, compared with 10
out of 75 (13.3%) in matched adjacent noncancerous
tissues (P < 0.0001) (Figure 1B). Then we investigated
possible correlations between GOLPH3 expression
and CRC clinicalpathological characteristics. Our data
showed that GOLPH3 expression was correlated with
gender (P = 0.007), recurrence (P = 0.006) and survival
(P = 0.014). However, no significant associations were
found between GOLPH3 expression and other clini-
copathological features (Table 1).
Association between GOLPH3 protein expression and
survival of patients treated with 5-FU-based adjuvant
chemotherapy
Kaplan-Meier survival curves and log-rank test survival
analysis were used to determine the prognostic value of
GOLPH3 on survival of patients who received 5-FU-
based adjuvant chemotherapy. The results showed that
patients with tumors exhibiting high GOLPH3 expres-
sion had substantially longer disease-free survival (DFS;
P = 0.002, Figure 2A) and overall survival (OS; P = 0.011,
Figure 2B) than those with tumors exhibiting low
GOLPH3 expression. These data suggest that highA level in CRC tissues (Tumor) and matched adjacent noncancerous
PH3 was normalized with GAPDH mRNA level. (B) Representative
staining in CRC tissues (T), and (b and d) staining of GOLPH3 in
0 × .
Figure 2 Kaplan-Meier curves for DFS and OS. High levels of GOLPH3 expression was significantly associated with favourable DFS (A) and OS
(B) in patients treated with 5-FU-based adjuvant chemotherapy.
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sis in patients treated with 5-FU adjuvant chemotherapy.
Furthermore, Cox proportional hazard regression
analysis was performed to evaluate the prognostic sig-
nificance of clinicopathological parameters. Univariate
analysis showed that high GOLPH3 expression was
significantly associated with longer DFS (HR, 0.334;
95%CI, 0.159-0.702; P = 0.004, Table 2) and OS (HR,
0.458; 95%CI, 0.245-0.853; P = 0.014, Additional file 2:
Table S2) in patients treated with 5-FU-based adjuvant
chemotherapy. All factors that showed prognostic sig-
nificance in the univariate analysis were included in
the multivariate analysis. Multivariate analysis showed
that GOLPH3 appeared to be an independent prognos-
tic factor for prolonged DFS (HR, 0.468; 95% CI, 0.222-
0.987; P = 0.046, Table 2). However, patients with high
levels of GOLPH3 expression retained only a border-
line significant association with favourable OS com-
pared to those with low levels of GOLPH3 expression
(HR, 0.557; 95%CI, 0.292-1.062; P = 0.076, Additional




Age (≥60 yr vs <60 yr) 1.037 0.583−
Gender (Male vs Female) 2.318 1.179−
Tumor location (Rectum vs Colon ) 0.958 0.476−
Tumor size (>4 cm vs ≤4 cm) 1.424 0.751−
TNM stage (III/IV vs II) 11.545 3.578−
Histological type (Mucinous Vs Adenocarcinoma) 1.086 0.337−
Tumor differentiation (Poor/moderate vs Well) 2.794 0.865−
GOLPH3 expression (High vs Low) 0.334 0.159−
HR hazard ratio, CI confidence interval, P values in bold were statistically significantGOLPH3 regulates 5-FU-induced cytotoxicity in CRC cells
Then we examined the contribution of GOLPH3 expres-
sion to 5-FU sensitivity in vitro. First, we measured the
expression of GOLPH3 in CRC cell lines, including
SW480, RKO, LoVo, HT29 and HCT116. qRT-PCR and
Western blot analysis showed that GOLPH3 was ubiqui-
tously expressed in all of five CRC cell lines at both
mRNA and protein levels (Additional file 3: Figure S1).
The highest GOLPH3 expression was detected in LoVo
cells while RKO cells showed the lowest GOLPH3 ex-
pression. Accordingly, RKO and LoVo cells were used
to perform the following experiments in vitro. Secondly,
to facilitate further study, we used either plasmid en-
coding full length of GOLPH3 or GOLPH3 siRNAs to
either overexpress or knockdown GOLPH3 levels in
CRC cells, respectively. Western blot analysis confirmed
the efficiency of GOLPH3 overexpression and knock-
down in CRC cells (Figure 3A and 3B). Since siRNA
pool (siG-pool, a combination of three independent siR-
NAs including siG-1, siG-2 and siG-3) could achieve
stronger on-target gene knockdown with minimal off-tients who received 5-FU-based chemotherapy with
P Multivariate P
CI HR 95% CI
1.844 0.901
4.556 0.015 2.011 0.980−4.128 0.057
1.929 0.904
2.699 0.279
37.253 <0.0001 29.406 4.031−214.527 <0.0001
3.501 0.89
9.025 0.086
0.702 0.004 0.468 0.222−0.987 0.046
.
Figure 3 GOLPH3 regulates 5-FU sensitivity in CRC cells. (A and B) Western blot analysis of GOLPH3 expression in RKO and LoVo cells transfected
with plasmid encoding full length of GOLPH3 or GOLPH3 siRNA pool (siG-pool). β-actin was used as a loading control. Cells were treated with
different concentrations of 5-FU (0, 12.5, 25, 50, 100, 200 μM). And cell viability was analyzed by MTT assay. The growth inhibition ratio increased
in GOLPH3-overexpressing CRC cells (C and E) and decreased in GOLPH3-silencing CRC cells (D and F) in a 5-FU dose-dependent manner. The
values are mean ± SD of three independent experiments, *P < 0.05 compared with control cells.
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siG-pool to silence GOLPH3 expression in CRC cells.
We further evaluated the effects of GOLPH3 expression
on the 5-FU cytotoxicity to RKO and LoVo cells using
MTT analysis. As shown in Figure 3C and 3E, overexpres-
sion of GOLPH3 significantly increased 5-FU-induced cyto-
toxicity in a dose-dependent manner in both RKO and
LoVo cells. Moreover, knockdown of GOLPH3 dramatically
decreased 5-FU-induced cell death and increased 5-FU
resistance in these cells (P < 0.05, Figure 3D and 3F). Our
results suggest that GOLPH3 played an important role in
CRC cell sensitivity to 5-FU.
GOLPH3 modulates 5-FU sensitivity through regulation of
5-FU-induced apoptosis
The effect of GOLPH3 on chemosensitivity was con-
firmed by analysing 5-FU-induced apoptosis. Flow cyto-
metric analysis showed that 5-FU-induced apoptosis was
significantly reduced in GOLPH3-silencing RKO and
LoVo cells (Figure 4 and Additional file 5: Figure S3),
and increased in GOLPH3-overexpressing cells, com-
pared with control cells (Additional file 6: Figure S4),
suggesting that GOLPH3 could sensitize 5-FU-induced
apoptosis.
Moreover, to further confirm the effect of GOLPH3 on
5-FU-induced apoptosis, changes in cleaved PARP were
detected by Western blot. PARP is a substrate of caspase-
3 and −7 which cleave it into 89 and 24 kDa fragments.
Cleavage of PARP is one of the classic markers for
activation of downstream signals during apoptosis [22].
Although the expression of GOLPH3 changed minimally
in CRC cells treated with increased doses of 5-FU
(Additional file 7: Figure S5), overexpression of GOLPH3
increased the cleaved PARP in both RKO and LoVo cells
administrated with 5-FU (Figure 5A and Figure 5C).
Moreover, knockdown of GOLPH3 by siRNA reduced
the cleavage of PARP in both cells under 5-FU treatmentFigure 4 Knockdown of GOLPH3 inhibited 5-FU-induced apoptosis in
siRNA pool (siG-pool) or control siRNA (siControl), and then treated with 5-
using Annexin-V-FITC and propidium iodide (PI) dual labelling. Data are pre
of cells examined. All experiments were performed in triplicate. The values(Figure 5B and Figure 5D). These results suggest that over-
expression of GOLPH3 sensitizes cells to 5-FU-induced
apoptosis, whereas down-regulation of GOLPH3 protects
cells against 5-FU-induced apoptosis.
Discussion
In the present study, we demonstrated that GOLPH3
was highly expressed in CRC tissues compared with
matched adjacent noncancerous tissues. High levels of
GOLPH3 expression were associated with prolonged
survival in CRC patients treated with postoperative 5-
FU-based adjuvant chemotherapy. And multivariate ana-
lysis identified GOLPH3 as an independent prognostic
factor for DFS. Furthermore, we found that overexpres-
sion of GOLPH3 could facilitate the cytotoxicity of 5-FU
to CRC cells, while knockdown of GOLPH3 hindered
the sensitivity of CRC cells to 5-FU-induced apoptosis
in vitro. These findings suggested that GOLPH3 modu-
lates 5-FU sensitivity and may serve as a potential indi-
cator to predict 5-FU chemosensitivity.
GOLPH3, which is a component of the Golgi matrix,
has been identified as a novel protooncogene by Scott
et al. since 2009 [10]. Recent clinical studies have indi-
cated that high levels of GOLPH3 expression promote
tumorigenesis and progression of several types of malig-
nancies, and correlates with poor survival in various
cancers [10-16]. In colon adenocarcinoma, it has been
revealed that GOLPH3 is amplified at the 5p13 region
[10]. It has been showed that tumors with high levels of
GOLPH3 were significantly more sensitive to rapamycin
treatment in vivo [10]. These findings suggest that
GOLPH3 may associate with tumor cell sensitivity to
anticancer agents. 5-FU-based adjuvant chemotherapy
is a standard treatment for patients with stage III to IV
CRC, and stage II CRC with a high risk of recurrence
[2-4]. Whether GOLPH3 plays a role in predicting the
therapeutic effect of 5-FU for individual patient is ourCRC cells. RKO (A) and LoVo (B) cells were transfected with GOLPH3
FU of 0 or 200 μM for 48 h. Apoptosis was detected by flow cytometry
sented as percentage of early and late apoptotic cells of total number
are mean ± SD, *P < 0.05.
Figure 5 (See legend on next page.)
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Figure 5 GOLPH3 regulated 5-FU-induced apoptosis via modulation of PARP cleavage. RKO and LoVo cells were transfected with
pCMV-Myc-GOLPH3/pCMV-Myc (GOLPH3 over-expression, A and C) or GOLPH3 siRNA pool (siG-pool)/control siRNA (siControl) (GOLPH3
silencing, B and D) and then treated with indicated concentrations of 5-FU (0, 100, 200 μM) for 48 h. Western blot analysis showed the alteration of
cleaved PARP and GOLPH3. Upper panels, one representative of three similar Western blot analysis. Lower panels, relative protein ratio were normalized
to β-actin. All data are mean ± SD, *P < 0.05.
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significance of GOLPH3 in patients treated with 5-FU-
based adjuvant chemotherapy, and the potential influ-
ence of GOLPH3 on adjuvant chemotherapy. Our study
revealed GOLPH3 expression was elevated in CRC tis-
sues compared with matched adjacent noncancerous
tissues. However, in contrast with other studies, our
results showed that high levels of GOLPH3 expression
indicated favourable prognosis in patients who underwent
5-FU-based adjuvant chemotherapy, suggesting that CRC
patients with tumors exhibiting high GOLPH3 exp-
ression may be more likely to benefit from 5-FU-based
adjuvant chemotherapy than those with tumors exhibit-
ing low GOLPH3 expression. Possible explanations for
these disparate findings between our study and others
may include different genetic features of patients, differ-
ent types of cancer or variable tumor stages, variable
doses and schedules of adjuvant chemotherapy among
previous studies, and limited amount of patients in
some studies. Moreover, although many oncogenes are
correlated with cell resistance to chemotherapy, there
are still some oncogenes which could enhance chemo-
therapeutic sensitivity and are correlated with pro-
longed survival [23-28]. For example, XB130 has been
reported to promote tumor cell proliferation, inhibit
apoptosis and increase cell invasion in esophageal squa-
mous cell carcinoma, lung and thyroid cancer [23-25].
However, in gastric cancer, patients with higher XB130
expression were found to have a better prognosis.
Meanwhile, patients with upregulated XB130 were more
sensitive to 5-FU and have a longer survival time [26].
Likewise, Fra-1 and ID1 have been proved to exert
oncogenic function in breast and prostate cancers,
whereas overexpression of these genes not only predict
better survival in cancer patients, but also sensitized
cancer cells to different chemotherapeutics [27,28].
Similarly, although GOLPH3 is a potent oncogene,
GOLPH3-expressing tumors were more sensitive to
rapamycin [10], as well as 5-FU in our study. Accord-
ingly, patients with high levels of GOLPH3 will be
more sensitive to 5-FU and have prolonged survival.
Since GOLPH3 plays critical roles in activating mTOR
signalling and conferring increased sensitivity to mTOR
inhibitor, rapamycin, whether GOLPH3 expression level
predicts sensitivity to chemotherapy agents, such as 5-FU,
need to be elucidated. In this study, we found that
GOLPH3 overexpression sensitized CRC cells to 5-FU-induced apoptosis in vitro. These results raise the possibil-
ity that the effects of GOLPH3 on cellular chemosensitiv-
ity contributes to the role of GOLPH3 in predicting
survival of CRC patients who received 5-FU-based ad-
juvant chemotherapy. Similarly, the chemosensitivity of
CRC cells to paclitaxel, a chemotherapy agent widely used
in advanced gastrointestinal carcinoma, was also found to
be modulated by GOLPH3 (Additional file 8: Figure S6).
Although more precise biochemical basis and mecha-
nisms for GOLPH3 in modulating the sensitivity to
cytotoxic drugs remains to be explored, our results indi-
cated that GOLPH3 may serve as a positive predictor of
5-FU sensitivity. To further validate our findings, pro-
spective randomized clinical studies for patients with
or without 5-FU treatment are required. Moreover, for
patients with recurrent or metastatic CRC, Response
Evaluation Criteria in Solid Tumors (RECIST) guide-
lines should be applied to evaluate the tumor response
and the clinical benefit from 5-FU-based chemotherapy
more precisely.
Conclusions
In conclusion, our study revealed that GOLPH3 expres-
sion could predict the clinical outcome in CRC patients
treated with postoperative 5-FU-based adjuvant chemo-
therapy. Patients with tumors exhibiting high GOLPH3
expression were more likely to benefit from 5-FU-based
adjuvant chemotherapy than those with tumors exhibiting
low GOLPH3 expression. Functionally, we showed that
GOLPH3 affected the sensitivity of CRC cells to 5-FU-
induced cytotoxity. Taken together, GOLPH3 may serve as
a potential indicator to predict 5-FU chemosensitivity.
Additional files
Additional file 1: Table S1. Primers and sequences.
Additional file 2: Table S2. Univariate and multivariate analysis of
GOLPH3 in patients who underwent 5-FU-based chemotherapy with
respect to OS.
Additional file 3: Figure S1. Expression of GOLPH3 in CRC cell lines.
GOLPH3 mRNA (A) and protein expression (B) in CRC cell lines (SW480,
RKO, LoVo, HT29, and HCT116) were determined by qRT-PCR and Western
blot, respectively. SW480 was used as a calibrator in ΔΔCt analysis for
qRT-PCR.
Additional file 4: Figure S2. Efficiency of siRNAs-mediated knockdown
of GOLPH3 in RKO cells. Knockdown of GOLPH3 was evaluated in RKO
cells transfected with GOLPH3 siRNAs (siG-1, siG-2, siG-3 or siG-pool) or
control siRNA (siControl) using (A) qRT-PCR and (B) Western blot. SiControl
was used as a calibrator in ΔΔCt analysis for qRT-PCR.
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http://www.translational-medicine.com/content/12/1/15Additional file 5: Figure S3. Influence of GOLPH3 silencing on 5-FU in-
duced CRC cell apoptosis. Fraction of apoptotic cells were analysed by flow
cytometry in siGOLPH3-transfected RKO (A) and LoVo cells (B) cultured
with or without 200 μM of 5-FU. The population of apoptotic cell was
calculated as the percentages of cells in the upper- and lower-right quad-
rants. All experiments were performed in triplicate.
Additional file 6: Figure S4. Overexpression of GOLPH3 sensitized 5-
FU-induced apoptosis in RKO cells in a dose-dependent manner. (A) RKO
cells were transfected with pCMV-Myc-GOLPH3 or control (pCMV-Myc),
and then treated with 5-FU of 0, 200 or 400 μM for 48 h. Apoptosis was
detected by flow cytometry using Annexin-V-FITC and propidium iodide
(PI) dual labelling. (B) Data are presented as percentage of early and late
apoptotic cells of total number of cells examined. All experiments were
performed in triplicate. The values are mean ± SD, *P < 0.05.
Additional file 7: Figure S5. 5-FU treatment does not affect the
protein level of GOLPH3. GOLPH3 expression was determined by Western
blot in RKO (A) and LoVo cells (B) treated with different concentrations of
5-FU.
Additional file 8: Figure S6. The expression of GOLPH3 and cleaved
PARP in RKO cells treated with paclitaxel. (A) Expression of GOLPH3
was determined by Western blot in RKO cells treated with various
concentrations of paclitaxel for 48 h. Paclitaxel treatment does not affect
GOLPH3 expression. (B) Knockdown of GOLPH3 reduced paclitaxel-induced
apoptosis. The cleavage of PARP in paclitaxel treated GOLPH3-silencing and
control cells was examined by Western blot. The results are representative of
three independent experiments.
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